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Background: Coinciding with the relatively good and improving prognosis for patients with stage I–III breast cancer, late
recurrences, new primary tumours and late side-effects of treatment may occur. We gained insight into prognosis for
long-term breast cancer survivors.
Patients and methods: Data on all 205 827 females aged 15–89 diagnosed with stage I–III breast cancer during
1989–2008 were derived from the Netherlands Cancer Registry. Conditional 5-year relative survival was calculated for
every subsequent year from diagnosis up to 15 years.
Results: For stage I, conditional 5-year relative survival remained ∼95% up to 15 years after diagnosis (a stable 5-year
excess mortality rate of 5%). For stage II, excess mortality remained 10% for those aged 15–44 or 45–59 and 15% for
those aged 60–74. For stage III, excess mortality decreased from 35% at diagnosis to 10% at 15 years for those aged
15–44 or 45–59, and from ∼40% to 30% for those aged ≥60.
Conclusions: Patients with stage I or II breast cancer had a (very) good long-term prognosis, albeit exhibiting a small
but significant excess mortality at least up to 15 years after diagnosis. Improvements albeit from a lower level were mainly
seen for patients who had been diagnosed with stage III disease. Caregivers can use this information to better inform
(especially disease-free) cancer survivors about their actual prognosis.
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introduction
In Western countries, breast cancer is the most frequent cancer
among females [1, 2]. Overall prognosis is good with a survival
rate of at least 80% at 5 years and over 70% at 10 years [2]. In
2015, about 190 000 Dutch females are estimated to be alive
after a former diagnosis of breast cancer in the preceding
10 years, representing ∼1.5% of the total female adult popula-
tion [3]. Breast cancer recurrences can occur many years after
diagnosis [4–6]. In addition, breast cancer patients have a
higher risk for new primary cancers [7] and cardiac diseases
may occur as a late side-effect of treatment [8]. This may all lead
to excess mortality compared with the general population.
Traditionally, survival estimates for cancer patients are re-
ported from the time of diagnosis. These survival projections
are not valid for patients who have already survived a period of
time after initial diagnosis and treatment. Conditional survival
analysis estimates the survival rate, given the pre-condition of
having already survived for some time, and can be used by care-
givers for informing cancer survivors about their estimated
actual prognosis during follow-up [9, 10].
Although some authors have published on conditional sur-
vival for breast cancer patients, most of them restricted the ana-
lyses to patients who had survived only 1 year or up to 5 years
after diagnosis, or did not report on detailed combinations of
age and stage groups [10–15].
In this study, we calculated conditional 5-year relative survival
rates for breast cancer patients, for each subsequent year sur-
vived up to 15 years after primary diagnosis.
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Population-based data from the nationwide Netherlands Cancer Registry
(NCR), which started in 1989 and is maintained and hosted by the
Comprehensive Cancer Centres, was used. The NCR is based on the notifica-
tion of all newly diagnosed malignancies by the automated national patho-
logical archive (PALGA). Additional sources are the national registry of
hospital discharge diagnoses, which account for up to an extra 8% of new
cases. Information on patient and tumour characteristics is routinely col-
lected from the medical records within about 9 months after diagnosis. The
quality of the data is high, thanks to thorough training of the registrars and
computerized consistency checks. Completeness is estimated to be at least
95%. In addition to the active and passive follow-up via the hospitals, date of
death is also retrieved from the Municipal Personal Records Database
(GBA). This database contains all deaths and emigrated persons in the
Netherlands since October 1994. For patients diagnosed before October
1994, follow-up was completed by merging the database with the municipal-
ity death records and/or with the Central Bureau for Genealogy, which regis-
ters all deaths in the Netherlands.
All female patients with invasive stage I–III primary breast cancer (C50, in-
cluding both unilateral and contralateral breast cancer) diagnosed in the
period 1989–2008 in the Netherlands were included (n = 205 827). This study
focussed on stage I–III patients, since stage IV patients generally have a
limited survival (median survival ∼2 years). Therefore, conditional survival
statistics are less useful and are also less stable due to small numbers. The date
of death was completed up to 2009. Patients younger than 15 years and older
than 89 years were excluded from the analysis, as well as cases diagnosed at
autopsy. Patients aged ≥89 years were excluded, because conditional survival
estimates are unreliable due to the lack of long follow-up for these patients.
Age was divided into four groups (15–44, 45–59, 60–74 and 75–89 years). Age
groups 15–29 and 30–44 years were merged, because results became relatively
unstable due to the small numbers of patients in the age group 15–29 years,
and prognosis does not differ significantly between subgroups of age for those
<40 years [16]. Stage was based on the pathological tumour–node–metastasis
(TNM) classification if available. Otherwise, clinical stage was used.
statistical analyses
Relative survival is calculated as the absolute survival among cancer patients
divided by the expected survival of a comparable group from the Dutch
general population (same period, age and gender) [17]. Period analysis was
used to provide up-to-date survival estimates [18]. Furthermore, hybrid ana-
lysis was used for situations, in which mortality data (follow-up of the study
population) are more up-to-date than incidence data [19]. Five-year relative
survival rates were calculated for every subsequent year survived up to
15 years after diagnosis, conditional on being alive at the beginning of that
year (conditional 5-year relative survival). Conditional survival was calcu-
lated for 15 years age groups, according to the stage of disease. We present
only conditional relative survival estimates with a standard error of ≤5% of
the survival rate.
When conditional 5-year relative survival is at or above the level of 95%,
there is minimal excess mortality for that group of patients. For the calcula-
tion of conditional 5-year relative survival estimates, a saturated Poisson re-
gression model for period analysis was used [20]. Standard errors of the
survival estimates were calculated using the delta method. Calculations were
carried out with SAS software (SAS system 9.2, SAS Institute, Cary, NC).
web-based tool
A web-based tool has been constructed to make the conditional relative sur-
vival estimates available for caregivers, who can use this tool for counselling
patients with stage I–III breast cancer during follow-up (www.
dutchcancersurvival.com).
results
Table 1 shows the numbers of patients available for the analyses,
including the last year for which a reliable estimate for the con-
ditional 5-year relative survival could be made, and conditional
5-year relative survival figures at diagnosis and for patients who
were alive 5, 10 and 15 years after diagnosis. In none of these
cases did the conditional 5-year relative survival rate exceed
95%, meaning that a small but significant 5-year excess mortal-
ity remained during follow-up.
conditional relative survival by stage and age
For patients with stage I disease, the 5-year relative survival at
diagnosis was 96%, being slightly poorer for patients aged 15–44
years (94%) compared with older patients (96%) (Table 1,
P < 0.05). This difference remained for conditional 5-year rela-
tive survival up to 5 years after diagnosis (Figure 1A). For the
total group of patients diagnosed with stage I breast cancer,
conditional 5-year relative survival remained ∼95% during
follow-up, implicating that a 5-year excess mortality rate of ∼5%
persisted.
For patients with stage II disease, the 5-year relative survival
at diagnosis ranged between 82% and 88% for the different age
groups (Table 1, P < 0.05). Conditional 5-year relative survival
slightly increased with every year survived, although a 5-year
excess mortality rate of ∼10% remained for those aged 15–44 or
45–59 years. This was ∼15% for patients aged 60–74 or 75–89
years (Figure 1B).
For patients with stage III disease, conditional 5-year relative
survival improved with every subsequent year of survival after
diagnosis, but remained clearly poorer for those aged 60–74 and
75–89 years, although increasing from around 60% at diagnosis
up to ∼70% after 8 years. This coincided with a decrease in
excess mortality from ∼40% to ∼30% compared with a decrease
from ∼30% to ∼10% among younger patients (Figure 1C).
Although 5-year relative survival at diagnosis for all age
groups combined was clearly different between stage I (96%),
stage II (86%) and stage III (64%) (Figure 2), the differences
became smaller with each subsequent year of survival after diag-
nosis. After 15 years, the 5-year excess mortality rates decreased
to ∼5% and ∼10% for stages I and II, respectively, while for
stage III patients it remained >10%, notwithstanding the strong
decrease in excess mortality since diagnosis (almost 40%)
(Figure 2).
discussion
Although long-term prognosis for patients with stage I–III
breast cancer is relatively good, a small but significant excess
mortality compared with the general population remained for
survivors even after prolonged follow-up up to 15 years.
It seems reasonable to assume that patients have minimal to
no excess mortality when conditional 5-year relative survival
exceeds 95% (survival is then almost similar to the general
population with the same age structure). Whereas long-term
excess mortality <5% has been described for other cancers
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[10, 11, 13, 14, 21–23], 5-year excess mortality for breast cancer
patients remained higher than 5%. This means that breast cancer
patients—even after prolonged follow-up—continue to have a
poorer survival compared with the general population. Potential
explanations for excess mortality for breast cancer patients
include late recurrences [4–6, 24], second tumours [7, 25, 26] and
late side-effects of breast cancer treatment [4, 26, 27].
Recurrences and progression from breast cancer occur (espe-
cially among patients with ER and/or PR positive tumours),
even many years after diagnosis, but can be treated better sys-
tematically nowadays [4–6, 24, 28, 29]. About 25% of all recur-
rences of breast cancer occur after 5 years of follow-up [4].
Second primary tumours occur in up to 15% of breast cancer
survivors [7, 25]. Among breast cancer patients younger than
50 years, radiotherapy increases the risk of lung cancer, especial-
ly in smokers, whereas the use of chemotherapy and hormonal
therapy was followed by a decreased risk of second cancers,
especially in the contralateral breast [7]. Among those aged
≥50 years, chemotherapy has been linked to an increased risk of
melanoma, uterine cancer and leukaemia, while hormonal
therapy contributed to an increased risk of uterine cancer [7].
Whether late side-effects of breast cancer treatment (especially
systemic treatment and radiotherapy) translate into long-term
excess mortality might be analysed by stratification according to
treatment. However, even in our nation-wide database containing
more than 200 000 patients, stratification according to treatment
(in addition to stage and age) would lead to subgroups that are
too small to estimate valid conditional 5-year relative survival
rates. Quite a few studies have shown an increased rate of
cardiac morbidity and mortality among patients with breast
cancer, especially after radiotherapy at young age and delivered
before the 1990s [4, 26, 27]. Cardiovascular diseases have
become an important cause of death in breast cancer survivors
[28, 30]. Modern techniques for planning and delivery of radio-
therapy including respiratory control, conformal therapy with
shielding of heart and lungs and intensity modulated radiation
therapy (IMRT) have decreased the risk for (late) cardiovascular
side-effects [31]. The more widespread use of the cardiotoxic
anthracycline-based chemotherapy yet with a lower tumour
relapse risk may also lead to an increased rate of cardiac mortal-
ity [32–34]. For that reason, non-anthracycline-based regimes
have been developed [35], although not all oncologists believe
that this provides the highest level of efficacy.
In our study, we found that older women with stage II or III
breast cancer had a poorer conditional 5-year relative survival
than younger patients, as was also found in previous studies [2].
This might be explained by a higher excess mortality due to co-
morbidity, second tumours or late side-effects of treatment. On
the other hand, the poorer prognosis that was found for younger
patients with stage I or II breast cancer might be explained by a
unique biologic entity driven by unifying oncogenic signaling
pathways and is characterized by less hormone sensitivity and
higher HER-2/EGFR expression [16].
Strengths of this study are the size of the population-based
cohort, completeness of the cancer registry data, length of
follow-up time and the fact that stratified conditional 5-year
relative survival rates based on important prognostic factors
(age, stage and period of diagnosis) could be carried out.
Table 1. Conditional survival from breast cancer in the Netherlands 1989–2008 (n = 205 827), according to the stage and age at diagnosis
Age at diagnosis
(years)
No. of patients available for






Conditional 5-year relative survival (%)








Stage I Overall 55 251 30 294 11 878 1576 15 96 (96–97) 94 (93–94) 94 (93–94) 94 (92–95)
15–44 6640 4355 2167 441 15 94 (93–94) 91 (91–92) 93 (92–94) 94 (93–96)
45–59 21 056 12 257 5072 685 15 96 (96–97) 94 (94–95) 95 (94–96) 94 (93–96)
60–74 21 488 11 513 4273 435 15 97 (97–98) 94 (94–95) 93 (92–95) 93 (89–97)
75–89 6068 2170 367 44 10 96 (94–97) 94 (91–97) 89 (81–97) –
Stage II Overall 60 525 30 768 11 755 1752 15 86 (85–86) 85 (85–86) 88 (87–88) 89 (88–91)
15–44 9897 5558 2516 487 15 84 (83–85) 85 (84–86) 89 (88–90) 93 (91–94)
45–59 23 524 12 761 5178 817 15 88 (87–88) 87 (86–87) 89 (89–90) 89 (88–91)
60–74 17 767 9460 3590 435 15 86 (85–87) 84 (83–85) 85 (83–86) 86 (82–90)
75–89 9337 2990 471 44 11 82 (80–83) 83 (81–85) 90 (83–97) –
Stage III Overall 8909 2947 965 159 15 64 (63–65) 70 (68–71) 77 (74–80) 87 (81–92)
15–44 1399 508 235 47 15 67 (65–69) 76 (73–79) 86 (82–90) 86 (79–93)
45–59 3226 1090 396 74 15 68 (67–70) 73 (71–75) 83 (79–86) 92 (87–98)
60–74 2450 903 286 35 11 64 (62–66) 66 (63–68) 66 (61–72) –
75–89 1834 446 49 15 6 56 (54–58) 65 (60–70) – –
Source: Netherlands Cancer Registry.
aYear is defined as the time after diagnosis.
bConditional survival figures are considered reliable when the standard error was ≤ 5% of the survival rate. Year is defined as the last year since
diagnosis for which a reliable conditional 5-year relative survival estimate could be provided.
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Limitations are the facts that we could not carry out analyses
according to some other important prognostic factors such as
histological grade and treatment. For example, in the
Netherlands, breast cancer screening was introduced between
the early 1990s and 1995. This has led to earlier detection and
an improved prognosis [36]. In addition, treatment of breast
cancer has also become more effective, yet with a higher risk of
cardiac mortality [33, 37]. For the interpretation of results, one
should take all these changes into account.
In conclusion, patients with stage I or II breast cancer had a
(very) good long-term prognosis, albeit exhibiting a small but
significant excess mortality at least up to 15 years after diagnosis.
Improvements albeit from a lower level were mainly seen for
patients who had been diagnosed with stage III disease. The
remaining excess mortality is likely to be partially related to late
recurrences and second tumours, but can also be explained by
late side-effects of breast cancer treatment. Caregivers can use
this information to better inform (especially disease-free) cancer
survivors about their actual prognosis.
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Figure 1. Conditional 5-year relative survival at every subsequent year of
survival after initial diagnosis of patients with breast cancer, according to the
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Figure 2. Conditional 5-year relative survival at every subsequent year of
survival after initial diagnosis of patients with breast cancer, according to the
stage. Source: Netherlands Cancer Registry.
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